Teleflex to Showcase its Peripheral Intervention Product Portfolio Highlighting the Arrow® OnControl® Powered Bone Access S...
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, will showcase its Peripheral Intervention
product portfolio including the Arrow® OnControl® Powered Bone
Access System and the MANTA™ Vascular Closure Device at the CIRSE
being held in Barcelona, Spain on September 07 – 11, 2019.
As the interventional cornerstone of Teleflex, we offer a
growing portfolio of specialty-focused solutions to support
interventionalists around the globe. Our products are known for
their innovative ability to simplify complex procedures and common
clinical challenges. Interventionalists worldwide rely on our
innovative solutions, such as the MANTA™ Device, the OnControl®
System, the Hunter™ Biopsy Sealing Device, the Arrow-Clark™
VectorFlow® Chronic Hemodialysis Catheter™, the Turnpike® Catheter,
the SuperCross® Microcatheter, Super Arrow-Flex® Sheaths and
Pronto® Extraction Catheters.
The CE Marked MANTA™ Vascular Closure Device is
specifically designed for closure of large bore femoral
arteriotomies following procedures utilizing devices or sheaths
ranging in size from 10F to 18F (with maximum outer diameters up to
25F). The SAFE MANTA IDE Clinical Trial demonstrated that the
median time from deployment to hemostasis was 24 seconds (65 second
mean time).1a Technical success was achieved in 97.7% of patients,
and a single device was deployed in 99.6% of cases.1b The
IDE-defined major complications1c, the primary safety end point for
the study, occurred in 5.3% of patients and Valve Academic Research
Consortium-2 (VARC-2) major vascular complications occurred in 4.2%
of cases.1 This VARC-2 rate is lower than published rates for
Teleflex will be running two Hands-on Device Training Sessions
during the congress:
- Vertebral Augmentation on Tuesday, September 10 (VA-HDT 1 from
09:30 to 11:00 & VA-HDT 2 from 12:30 to 14:00) where we will
showcase our OnControl® System
- A closer look at closure devices on Saturday, September 7
(CD-HDT 1 from 09:30 to 11:00 & CD-HDT 2 from 12:30 to 14:00)
where we will showcase the MANTA™ Vascular Closure Device
Clinicians worldwide rely on the quality and proven clinical
utility of our peripheral intervention portfolio.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
VectorFlow is a trademark or registered trademark of Aegis
Medical Technologies, LLC.Teleflex, the Teleflex logo, Arrow,
Arrow-Clark, Arrow-Flex, Deknatel, Hudson RCI, Hunter, LMA, MANTA,
OnControl, Pilling, Pronto, Rüsch, SuperCross, Turnpike, UroLift,
and Weck are trademarks or registered trademarks of Teleflex
Incorporated or its affiliates, in the U.S. and/or other countries.
countries © 2019 Teleflex Incorporated. All rights reserved.
References: 1. Wood D, et al. Pivotal Clinical
Study to Evaluate the Safety and Effectiveness of the MANTA
Percutaneous Vascular Closure Device: The SAFE MANTA Study.
Circulation: Cardiovascular Interventions. 2019 July. Vol 12, Issue
7.a. MANTA™ Device demonstrated a time to hemostasis of 24 seconds
median time (65 seconds mean time) from deployment to hemostasis.b.
Percutaneous vascular closure obtained with the MANTA™ Device
without the use of unplanned endovascular or
surgical intervention.c. Major complications defined as
composite of i) vascular injury requiring surgical
repair/stent-graft; ii) bleeding requiring transfusion; iii)
lower extremity ischemia requiring surgical repair/additional
percutaneous intervention; iv) nerve injury (permanent or requiring
surgical repair); and v) infection requiring IV antibiotics and/or
extended hospitalization. Study sponsored by Teleflex Incorporated
or its affiliates.2. Généreux P, et al. Vascular complications
after transcatheter aortic valve replacement. J Am Coll Cardiol.
2012 Sept 18;60(12):1043-1052.3. Lauten A, et al. Percutaneous
left-ventricular support with the Impella 2.5®-assist device in
acute cardiogenic shock: results of the Impella-EUROSHOCK-registry.
Circ Heart Fail. 2013 Jan;6(1):23-30.
Source: Teleflex IncorporatedJake
ElguiczeTreasurer and Vice President, Investor
Historical Stock Chart
From Nov 2020 to Dec 2020
Historical Stock Chart
From Dec 2019 to Dec 2020